| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Beth Israel Deaconess Medical Center, Boston, MA 02215;
Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; and
Merck Research Laboratories, West Point, PA 19486
Virus-specific CD4+ T cell responses have been shown to play a critical role in controlling HIV-1 replication. Candidate HIV-1 vaccines should therefore elicit potent CD4+ as well as CD8+ T cell responses. In this report we investigate the ability of plasmid GM-CSF to augment CD4+ T cell responses elicited by an HIV-1 gp120 DNA vaccine in mice. Coadministration of a plasmid expressing GM-CSF with the gp120 DNA vaccine led to only a marginal increase in gp120-specific splenocyte CD4+ T cell responses. However, immunization with a bicistronic plasmid that coexpressed gp120 and GM-CSF under control of a single promoter led to a dramatic augmentation of vaccine-elicited CD4+ T cell responses, as measured by both cellular proliferation and ELISPOT assays. This augmentation of CD4+ T cell responses was selective, since vaccine-elicited Ab and CD8+ T cell responses were not significantly changed by the addition of GM-CSF. A 100-fold lower dose of the gp120/GM-CSF bicistronic DNA vaccine was required to elicit detectable gp120-specific splenocyte proliferative responses compared with the monocistronic gp120 DNA vaccine. Consistent with these findings, i.m. injection of the gp120/GM-CSF bicistronic DNA vaccine evoked a more extensive cellular infiltrate at the site of inoculation than the monocistronic gp120 DNA vaccine. These results demonstrate that bicistronic DNA vaccines containing GM-CSF elicit remarkably potent CD4+ T cell responses and suggest that optimal Th cell priming requires the precise temporal and spatial codelivery of Ag and GM-CSF.
This article has been cited by other articles:
|
|
 |
|
  J. Liu, R. Kjeken, I. Mathiesen, and D. H. Barouch Recruitment of Antigen-Presenting Cells to the Site of Inoculation and Augmentation of Human Immunodeficiency Virus Type 1 DNA Vaccine Immunogenicity by In Vivo Electroporation J. Virol., June 1, 2008; 82(11): 5643 - 5649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Schoenly and D. B. Weiner Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business" J. Virol., April 1, 2008; 82(7): 3166 - 3180. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Geiben-Lynn, J. R. Greenland, K. Frimpong-Boateng, and N. L. Letvin Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses Clin. Vaccine Immunol., April 1, 2008; 15(4): 691 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qin, J. R. Greenland, C. Moriya, M. J. Cayabyab, and N. L. Letvin Effects of Type I Interferons on the Adjuvant Properties of Plasmid Granulocyte-Macrophage Colony-Stimulating Factor In Vivo J. Virol., October 1, 2007; 81(19): 10606 - 10613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hu, X. Lu, L. Tao, B. Bai, Z. Zhang, Y. Chen, F. Zheng, J. Chen, Z. Chen, and H. Wang Induction of Specific Immune Responses by Severe Acute Respiratory Syndrome Coronavirus Spike DNA Vaccine with or without Interleukin-2 Immunization Using Different Vaccination Routes in Mice Clin. Vaccine Immunol., July 1, 2007; 14(7): 894 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Greenland, R. Geiben, S. Ghosh, W. A. Pastor, and N. L. Letvin Plasmid DNA Vaccine-Elicited Cellular Immune Responses Limit In Vivo Vaccine Antigen Expression through Fas-Mediated Apoptosis J. Immunol., May 1, 2007; 178(9): 5652 - 5658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Skountzou, F.-S. Quan, S. Gangadhara, L. Ye, A. Vzorov, P. Selvaraj, J. Jacob, R. W. Compans, and S.-M. Kang Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- Macrophage Colony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles J. Virol., February 1, 2007; 81(3): 1083 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wang, S. A. Gujar, L. Cova, and T. I. Michalak Bicistronic Woodchuck Hepatitis Virus Core and Gamma Interferon DNA Vaccine Can Protect from Hepatitis but Does Not Elicit Sterilizing Antiviral Immunity J. Virol., January 15, 2007; 81(2): 903 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gupta, C. M. Leutenegger, G. A. Dean, J. D. Steckbeck, K. S. Cole, and E. E. Sparger Vaccination of Cats with Attenuated Feline Immunodeficiency Virus Proviral DNA Vaccine Expressing Gamma Interferon J. Virol., January 15, 2007; 81(2): 465 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hanke, A. J. McMichael, and L. Dorrell Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction J. Gen. Virol., January 1, 2007; 88(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kornbluth and G. W. Stone Immunostimulatory combinations: designing the next generation of vaccine adjuvants J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chavan, K. A. Marfatia, I. C. An, D. A. Garber, and M. B. Feinberg Expression of CCL20 and Granulocyte-Macrophage Colony-Stimulating Factor, but Not Flt3-L, from Modified Vaccinia Virus Ankara Enhances Antiviral Cellular and Humoral Immune Responses. J. Virol., August 1, 2006; 80(15): 7676 - 7687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ramsburg, J. Publicover, L. Buonocore, A. Poholek, M. Robek, A. Palin, and J. K. Rose A Vesicular Stomatitis Virus Recombinant Expressing Granulocyte-Macrophage Colony-Stimulating Factor Induces Enhanced T-Cell Responses and Is Highly Attenuated for Replication in Animals J. Virol., December 15, 2005; 79(24): 15043 - 15053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Mwangi, W. C. Brown, G. A. Splitter, Y. Zhuang, K. Kegerreis, and G. H. Palmer Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection J. Leukoc. Biol., August 1, 2005; 78(2): 401 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Barouch, Z.-y. Yang, W.-p. Kong, B. Korioth-Schmitz, S. M. Sumida, D. M. Truitt, M. G. Kishko, J. C. Arthur, A. Miura, J. R. Mascola, et al. A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates J. Virol., July 15, 2005; 79(14): 8828 - 8834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, A. A. C. Lemckert, R. Vogels, J. H. H. V. Custers, M. M. Addo, S. Lockman, T. Peter, F. W. Peyerl, M. G. Kishko, et al. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein J. Immunol., June 1, 2005; 174(11): 7179 - 7185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Sumida, D. M. Truitt, M. G. Kishko, J. C. Arthur, S. S. Jackson, D. A. Gorgone, M. A. Lifton, W. Koudstaal, M. G. Pau, S. Kostense, et al. Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors J. Virol., March 15, 2004; 78(6): 2666 - 2673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Ismael, D. Sekkai, C. Collin, D. Bout, and M.-N. Mevelec The MIC3 Gene of Toxoplasma gondii Is a Novel Potent Vaccine Candidate against Toxoplasmosis Infect. Immun., November 1, 2003; 71(11): 6222 - 6228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Nayak, G. Sailaja, and A. M. Jabbar Enhancement of gp120-Specific Immune Responses by Genetic Vaccination with the Human Immunodeficiency Virus Type 1 Envelope Gene Fused to the Gene Coding for Soluble CTLA4 J. Virol., October 15, 2003; 77(20): 10850 - 10861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Mascola, M. G. Lewis, T. C. VanCott, G. Stiegler, H. Katinger, M. Seaman, K. Beaudry, D. H. Barouch, B. Korioth-Schmitz, G. Krivulka, et al. Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies J. Virol., October 1, 2003; 77(19): 10348 - 10356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Barouch, P. F. McKay, S. M. Sumida, S. Santra, S. S. Jackson, D. A. Gorgone, M. A. Lifton, B. K. Chakrabarti, L. Xu, G. J. Nabel, et al. Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines J. Virol., August 15, 2003; 77(16): 8729 - 8735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. McClure, T. R. Hercus, B. A. Cambareri, J. M. Woodcock, C. J. Bagley, G. J. Howlett, and A. F. Lopez Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex Blood, February 15, 2003; 101(4): 1308 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Mwangi, W. C. Brown, H. A. Lewin, C. J. Howard, J. C. Hope, T. V. Baszler, P. Caplazi, J. Abbott, and G. H. Palmer DNA-Encoded Fetal Liver Tyrosine Kinase 3 Ligand and Granulocyte Macrophage-Colony-Stimulating Factor Increase Dendritic Cell Recruitment to the Inoculation Site and Enhance Antigen-Specific CD4+ T Cell Responses Induced by DNA Vaccination of Outbred Animals J. Immunol., October 1, 2002; 169(7): 3837 - 3846. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
